Retatrutide 20 mg vial is an investigational medication designed for the treatment of type 2 diabetes and obesity. It belongs to a novel class of drugs called triple‑agonist peptides, simultaneously activating the glucagon‑like peptide‑1 (GLP‑1), glucose‑dependent insulinotropic polypeptide (GIP), and glucagon receptors. By mimicking the actions of these three gut hormones, retatrutide enhances insulin secretion when blood glucose is elevated, reduces glucagon output, slows gastric empty‑time, and curbs appetite, leading to improved glycemic control and significant weight loss.

Mechanism of action

• GLP‑1 receptor activation: Boosts glucose‑dependent insulin release, suppresses inappropriate glucagon secretion, and promotes satiety.
• GIP receptor activation: Further amplifies insulin secretion and may improve lipid metabolism.
• Glucagon receptor activation: Increases energy expenditure and supports weight reduction through enhanced lipolysis.

Potential benefits

• Lowered HbA1c and fasting glucose levels.
• Substantial reductions in body weight (clinical trials have shown double‑digit percentage losses).
• Improved cardiovascular risk markers (blood pressure, lipid profile).